Literature DB >> 25795343

Risky decision-making and ventral striatal dopamine responses to amphetamine: a positron emission tomography [(11)C]raclopride study in healthy adults.

Lynn M Oswald1, Gary S Wand2, Dean F Wong3, Clayton H Brown4, Hiroto Kuwabara5, James R Brašić5.   

Abstract

Recent functional magnetic resonance imaging (fMRI) studies have provided compelling evidence that corticolimbic brain regions are integrally involved in human decision-making. Although much less is known about molecular mechanisms, there is growing evidence that the mesolimbic dopamine (DA) neurotransmitter system may be an important neural substrate. Thus far, direct examination of DA signaling in human risk-taking has centered on gambling disorder. Findings from several positron emission tomography (PET) studies suggest that dysfunctions in mesolimbic DA circuits may play an important role in gambling behavior. Nevertheless, interpretation of these findings is currently hampered by a need for better understanding of how individual differences in regional DA function influence normative decision-making in humans. To further our understanding of these processes, we used [(11)C]raclopride PET to examine associations between ventral striatal (VS) DA responses to amphetamine (AMPH) and risky decision-making in a sample of healthy young adults with no history of psychiatric disorder, Forty-five male and female subjects, ages 18-29 years, completed a computerized version of the Iowa Gambling Task. Participants then underwent two 90-minute PET studies with high specific activity [(11)C]raclopride. The first scan was preceded by intravenous saline; the second, by intravenous AMPH (0.3mg/kg). Findings of primary analyses showed that less advantageous decision-making was associated with greater right VS DA release; the relationship did not differ as a function of gender. No associations were observed between risk-taking and left VS DA release or baseline D2/D3 receptor availability in either hemisphere. Overall, the results support notions that variability in striatal DA function may mediate inter-individual differences in risky decision-making in healthy adults, further suggesting that hypersensitive DA circuits may represent a risk pathway in this population.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Amphetamine; Decision-making; Dopamine; Human; Positron emission tomography (PET); Ventral striatum

Mesh:

Substances:

Year:  2015        PMID: 25795343      PMCID: PMC4433778          DOI: 10.1016/j.neuroimage.2015.03.022

Source DB:  PubMed          Journal:  Neuroimage        ISSN: 1053-8119            Impact factor:   6.556


  115 in total

1.  Neural processing of risk.

Authors:  Peter N C Mohr; Guido Biele; Hauke R Heekeren
Journal:  J Neurosci       Date:  2010-05-12       Impact factor: 6.167

2.  Risk taking differences on a behavioral task as a function of potential reward/loss magnitude and individual differences in impulsivity and sensation seeking.

Authors:  Marina A Bornovalova; Alex Cashman-Rolls; Jennifer M O'Donnell; Kenneth Ettinger; Jerry B Richards; H deWit; C W Lejuez
Journal:  Pharmacol Biochem Behav       Date:  2008-11-14       Impact factor: 3.533

3.  Striatal dopamine release codes uncertainty in pathological gambling.

Authors:  Jakob Linnet; Kim Mouridsen; Ericka Peterson; Arne Møller; Doris Jeanne Doudet; Albert Gjedde
Journal:  Psychiatry Res       Date:  2012-08-11       Impact factor: 3.222

4.  Excessive Internet gaming and decision making: do excessive World of Warcraft players have problems in decision making under risky conditions?

Authors:  Mirko Pawlikowski; Matthias Brand
Journal:  Psychiatry Res       Date:  2011-06-17       Impact factor: 3.222

5.  Decision-making deficits in normal elderly persons associated with executive personality disturbances.

Authors:  Christopher M Nguyen; Joseph Barrash; Anna L Koenigs; Antoine Bechara; Daniel Tranel; Natalie L Denburg
Journal:  Int Psychogeriatr       Date:  2013-08-02       Impact factor: 3.878

6.  Inverse association between dopaminergic neurotransmission and Iowa Gambling Task performance in pathological gamblers and healthy controls.

Authors:  Jakob Linnet; Arne Møller; Ericka Peterson; Albert Gjedde; Doris Doudet
Journal:  Scand J Psychol       Date:  2011-02

7.  Dopamine transmission in the human striatum during monetary reward tasks.

Authors:  David H Zald; Isabelle Boileau; Wael El-Dearedy; Roger Gunn; Francis McGlone; Gabriel S Dichter; Alain Dagher
Journal:  J Neurosci       Date:  2004-04-28       Impact factor: 6.167

8.  Irrational choice under uncertainty correlates with lower striatal D(2/3) receptor binding in rats.

Authors:  Paul J Cocker; Katherine Dinelle; Rick Kornelson; Vesna Sossi; Catharine A Winstanley
Journal:  J Neurosci       Date:  2012-10-31       Impact factor: 6.167

9.  Amphetamine sensitization alters reward processing in the human striatum and amygdala.

Authors:  Owen G O'Daly; Daniel Joyce; Derek K Tracy; Adnan Azim; Klaas E Stephan; Robin M Murray; Sukhwinder S Shergill
Journal:  PLoS One       Date:  2014-04-09       Impact factor: 3.240

10.  Dopamine agonist increases risk taking but blunts reward-related brain activity.

Authors:  Jordi Riba; Ulrike M Krämer; Marcus Heldmann; Sylvia Richter; Thomas F Münte
Journal:  PLoS One       Date:  2008-06-25       Impact factor: 3.240

View more
  10 in total

Review 1.  The pharmacology of amphetamine and methylphenidate: Relevance to the neurobiology of attention-deficit/hyperactivity disorder and other psychiatric comorbidities.

Authors:  Stephen V Faraone
Journal:  Neurosci Biobehav Rev       Date:  2018-02-08       Impact factor: 8.989

2.  Brexpiprazole reduces hyperactivity, impulsivity, and risk-preference behavior in mice with dopamine transporter knockdown-a model of mania.

Authors:  Morgane Milienne-Petiot; Mark A Geyer; Jørn Arnt; Jared W Young
Journal:  Psychopharmacology (Berl)       Date:  2017-02-03       Impact factor: 4.530

3.  Beyond Sensation Seeking: A Conceptual Framework for Individual Differences in Psychostimulant Drug Effects in Healthy Humans.

Authors:  Tara L White
Journal:  Curr Opin Behav Sci       Date:  2017-02

Review 4.  Evaluating the evidence for sex differences: a scoping review of human neuroimaging in psychopharmacology research.

Authors:  Korrina A Duffy; C Neill Epperson
Journal:  Neuropsychopharmacology       Date:  2021-11-03       Impact factor: 7.853

5.  Sex-Dependent Alterations in the mRNA Expression of Enzymes Involved in Dopamine Synthesis and Breakdown After Methamphetamine Self-Administration.

Authors:  Aaron E Miller; Atul P Daiwile; Jean Lud Cadet
Journal:  Neurotox Res       Date:  2022-07-14       Impact factor: 3.978

6.  Dopamine, depressive symptoms, and decision-making: the relationship between spontaneous eye blink rate and depressive symptoms predicts Iowa Gambling Task performance.

Authors:  Kaileigh A Byrne; Dominique D Norris; Darrell A Worthy
Journal:  Cogn Affect Behav Neurosci       Date:  2016-02       Impact factor: 3.282

7.  Comments and controversies: Piecing together the neurobiology of decision-making.

Authors:  Lynn M Oswald; Gary S Wand
Journal:  Neuroimage       Date:  2015-08-15       Impact factor: 6.556

8.  Amplified Striatal Responses to Near-Miss Outcomes in Pathological Gamblers.

Authors:  Guillaume Sescousse; Lieneke K Janssen; Mahur M Hashemi; Monique H M Timmer; Dirk E M Geurts; Niels P Ter Huurne; Luke Clark; Roshan Cools
Journal:  Neuropsychopharmacology       Date:  2016-03-23       Impact factor: 7.853

9.  Is there a relation between novelty seeking, striatal dopamine release and frontal cortical thickness?

Authors:  Natalia Jaworska; Sylvia M Cox; Kevin F Casey; Isabelle Boileau; Mariya Cherkasova; Kevin Larcher; Alain Dagher; Chawki Benkelfat; Marco Leyton
Journal:  PLoS One       Date:  2017-03-27       Impact factor: 3.240

10.  Serotonin concentration enhancers at clinically relevant doses reduce [11C]AZ10419369 binding to the 5-HT1B receptors in the nonhuman primate brain.

Authors:  Kai-Chun Yang; Akihiro Takano; Christer Halldin; Lars Farde; Sjoerd J Finnema
Journal:  Transl Psychiatry       Date:  2018-07-16       Impact factor: 6.222

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.